Home / Resource Library / Phase 1/2 of Acalabrutinib Plus Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 of Acalabrutinib Plus Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

EHA 2019: Abstract of a study examining acalabrutinib combined with pembrolizumab for relapsed DLBCL.